Sanofi has made a $625m multi-year commitment to its corporate venture capital arm, Sanofi Ventures – bringing total assets under management to more than $1.4bn.
Since its inception in 2012, Sanofi Ventures has invested more than $800m across over 70 biotech, AI and digital health companies that align with Sanofi’s long-term growth ambitions. The evergreen fund focuses on the company’s core therapeutic areas, including immunology, rare diseases, neurology and vaccines.
“With a proven track record of strategic wins and successful exits, Sanofi Ventures has become a powerful engine for scientific progress and strategic growth,” said Paul Hudson, Chief Executive Officer at Sanofi. “By strengthening our investment capabilities, we are accelerating our ability to bring next-generation therapies that improve people’s lives while building valuable partnerships across the healthcare ecosystem.”
The additional funding comes at a time when early-stage biotech is facing a challenging financing environment. Ongoing market volatility, reduced venture inflows and pressure on valuations have made it increasingly difficult for startups to secure backing in the US and beyond. Sanofi’s increased commitment positions the fund as a solid source of capital and strategic support for emerging healthcare companies.
Jason Hafler, Managing Director, Sanofi Ventures, added: “The strong performance of our fund, including three realised exits in 2024 from companies with a combined acquisition value of $3.25bn, validates our evergreen structure and approach to identifying and supporting companies that are at the forefront of medical innovation.”
Sanofi Ventures invests across all stages of a private company’s lifecycle, from seed to crossover, and actively supports companies through to IPO.
